ME03561B - SOJ BAKTERIJA DOMAĆINA KOJI SADRŽI MUTIRANI SPR GEN I DIVLJI TIP Tsp GENA - Google Patents
SOJ BAKTERIJA DOMAĆINA KOJI SADRŽI MUTIRANI SPR GEN I DIVLJI TIP Tsp GENAInfo
- Publication number
- ME03561B ME03561B MEP-2019-281A MEP2019281A ME03561B ME 03561 B ME03561 B ME 03561B ME P2019281 A MEP2019281 A ME P2019281A ME 03561 B ME03561 B ME 03561B
- Authority
- ME
- Montenegro
- Prior art keywords
- mutated
- gene
- protein
- recombinant
- cell
- Prior art date
Links
- 101150081864 Spr gene Proteins 0.000 title claims description 20
- 241000894006 Bacteria Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 230000002759 chromosomal effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 210000001322 periplasm Anatomy 0.000 claims description 4
- 108090000316 Pitrilysin Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 230000006320 pegylation Effects 0.000 claims description 2
- 230000012846 protein folding Effects 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/22—Processes using, or culture media containing, cellulose or hydrolysates thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/26—Processes using, or culture media containing, hydrocarbons
- C12N1/28—Processes using, or culture media containing, hydrocarbons aliphatic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
SOJ BAKTERIJA DOMAĆINA KOJI SADRŽI MUTIRANI SPR GEN I DIVLJI TIP Tsp GENA
Patentni Zahtevi
1. Postupak za proizvodnju rekombinantnog proteina od interesa koji obuhvata kultivaciju rekombinantne gram-negativne bakterijske ćelije u medijumu kulture pod uslovima koji su efikasni za ekspresiju rekombinantnog proteina od interesa i izdvajanje rekombinantnog proteina od interesa iz periplazme rekombinantne gram-negativne bakterijske ćelije i/ili medijuma kulture, naznačen time što rekombinantna gram-negativna bakterijska ćelija sadrži
(a) mutirani spr gen koji kodira mutirani spr protein koji može da suzbije fenotip ćelije koji sadrži mutirani Tsp gen, naznačen time što mutirani spr gen kodira spr protein koji ima mutaciju u aminokiselini H145 prema aminokiselinskoj sekvenci SEK ID NO: 21, i
(b) nerekombinantni divlji tip hromozomskog Tsp gena,
naznačen time što je ćelija izogenična sa divljim tipom ćelije E. coli, osim za mutirani spr gen.
2. Postupak prema patentnom zahtevu 1, naznačen time što mutirani spr gen kodira spr protein koji ima mutaciju H145A, u skladu sa aminokiselinskom sekvencom SEK ID NO: 21.
3. Postupak prema bilo kojem od patentnih zahteva 1 ili 2, naznačen time, što ćelija dalje sadrži i rekombinantni polinukleotid koji kodira DsbC.
4. Postupak prema bilo kojem od patentnih zahteva od 1 do 3, naznačen time što ćelija dalje sadrži jedan ili više od sledećih mutiranih gena:
a) mutirani DegP gen koji kodira DegP protein koji ima aktivnost šaperona i smanjenu proteaznu aktivnost;
b) mutirani ptr gen, pri čemu mutirani ptr gen kodira protein Proteaza III koji ima smanjenu proteaznu aktivnost ili je mutirani nokaut ptr gen; i
c) mutirani OmpT gen, pri čemu mutirani OmpT gen kodira OmpT protein koji ima smanjenu proteaznu aktivnost ili je mutirani nokaut OmpT gen.
5. Postupak prema bilo kojem od patentnih zahteva od 1 do 4, naznačen time što ćelija sadrži vektor koji sadrži rekombinantni polinukleotid koji kodira DsbC i polinukleotidnu sekvencu koja kodira protein od interesa.
6. Postupak prema patentnom zahtevu 5, naznačen time što vektor sadrži promoter koji kontroliše ekspresiju rekombinantnog polinukleotida koji kodira DsbC i polinukleotidnu sekvencu koja kodira protein od interesa.
7. Postupak prema patentnom zahtevu 5 ili 6, naznačen time što je protein od interesa antitelo ili njegov antigen vezujući fragment.
8. Postupak prema patentnom zahtevu 7, naznačen time što je antitelo ili njegov antigen vezujući fragment specifičan za TNF.
9. Postupak prema bilo kojem od patentnih zahteva od 1 do 8, naznačen time što se rekombinantni protein od interesa dobija iz periplazme i/ili supernatanta.
10. Postupak prema patentnom zahtevom 9, naznačen time što sadrži dalji korak prerade proteina od interesa PEGilacijom.
11. Postupak prema bilo kojem od prethodnog patentnog zahteva, naznačen time što je ćelija E. coli W3110.
12. Rekombinantna gram-negativna bakterijska ćelija koja sadrži:
(a) mutirani spr gen koji kodira mutirani spr protein sposoban za supresiju fenotipa ćelije koja sadrži mutirani Tsp gen naznačen time što mutirani spr gen kodira spr protein koji ima mutaciju u aminokiselini H145 prema aminokiselinskoj sekvenci SEK ID NO: 21, i
(b) nerekombinantni hromozomski Tsp gen divljeg tipa,
naznačen time što je ćelija izogenična sa divljim tipom E. coli ćelije osim za mutirani spr gen.
13. Rekombinantna ćelija E. coli W3110 koja sadrži:
(a) mutirani spr gen koji kodira mutirani spr protein koji može da suzbije fenotip ćelije koja sadrži mutirani Tsp gen, pri čemu mutirani spr gen kodira spr protein koji ima mutaciju u aminokiselini H145 prema aminokiselinskoj sekvenci SEK ID NO: 21, i
(b) nerekombinantni hromozomski Tsp gen divljeg tipa.
2
Claims (13)
1. Postupak za proizvodnju rekombinantnog proteina od interesa koji obuhvata kultivaciju rekombinantne gram-negativne bakterijske ćelije u medijumu kulture pod uslovima koji su efikasni za ekspresiju rekombinantnog proteina od interesa i izdvajanje rekombinantnog proteina od interesa iz periplazme rekombinantne gram-negativne bakterijske ćelije i/ili medijuma kulture, naznačen time što rekombinantna gram-negativna bakterijska ćelija sadrži(a) mutirani spr gen koji kodira mutirani spr protein koji može da suzbije fenotip ćelije koji sadrži mutirani Tsp gen, naznačen time što mutirani spr gen kodira spr protein koji ima mutaciju u aminokiselini H145 prema aminokiselinskoj sekvenci SEK ID NO: 21, i(b) nerekombinantni divlji tip hromozomskog Tsp gena, naznačen time što je ćelija izogenična sa divljim tipom ćelije E. coli, osim za mutirani spr gen.
2. Postupak prema patentnom zahtevu 1, naznačen time što mutirani spr gen kodira spr protein koji ima mutaciju H145A, u skladu sa aminokiselinskom sekvencom SEK ID NO: 21.
3. Postupak prema bilo kojem od patentnih zahteva 1 ili 2, naznačen time, što ćelija dalje sadrži i rekombinantni polinukleotid koji kodira DsbC.
4. Postupak prema bilo kojem od patentnih zahteva od 1 do 3, naznačen time što ćelija dalje sadrži jedan ili više od sledećih mutiranih gena:a) mutirani DegP gen koji kodira DegP protein koji ima aktivnost šaperona i smanjenu proteaznu aktivnost;b) mutirani ptr gen, pri čemu mutirani ptr gen kodira protein Proteaza III koji ima smanjenu proteaznu aktivnost ili je mutirani nokaut ptr gen; ic) mutirani OmpT gen, pri čemu mutirani OmpT gen kodira OmpT protein koji ima smanjenu proteaznu aktivnost ili je mutirani nokaut OmpT gen.
5. Postupak prema bilo kojem od patentnih zahteva od 1 do 4, naznačen time što ćelija sadrži vektor koji sadrži rekombinantni polinukleotid koji kodira DsbC i polinukleotidnu sekvencu koja kodira protein od interesa.
6. Postupak prema patentnom zahtevu 5, naznačen time što vektor sadrži promoter koji kontroliše ekspresiju rekombinantnog polinukleotida koji kodira DsbC i polinukleotidnu sekvencu koja kodira protein od interesa.
7. Postupak prema patentnom zahtevu 5 ili 6, naznačen time što je protein od interesa antitelo ili njegov antigen vezujući fragment.
8. Postupak prema patentnom zahtevu 7, naznačen time što je antitelo ili njegov antigen vezujući fragment specifičan za TNF.
9. Postupak prema bilo kojem od patentnih zahteva od 1 do 8, naznačen time što se rekombinantni protein od interesa dobija iz periplazme i/ili supernatanta.
10. Postupak prema patentnom zahtevom 9, naznačen time što sadrži dalji korak prerade proteina od interesa PEGilacijom.
11. Postupak prema bilo kojem od prethodnog patentnog zahteva, naznačen time što je ćelija E. coli W3110.
12. Rekombinantna gram-negativna bakterijska ćelija koja sadrži:(a) mutirani spr gen koji kodira mutirani spr protein sposoban za supresiju fenotipa ćelije koja sadrži mutirani Tsp gen naznačen time što mutirani spr gen kodira spr protein koji ima mutaciju u aminokiselini H145 prema aminokiselinskoj sekvenci SEK ID NO: 21, i(b) nerekombinantni hromozomski Tsp gen divljeg tipa, naznačen time što je ćelija izogenična sa divljim tipom E. coli ćelije osim za mutirani spr gen.
13. Rekombinantna ćelija E. coli W3110 koja sadrži:(a) mutirani spr gen koji kodira mutirani spr protein koji može da suzbije fenotip ćelije koja sadrži mutirani Tsp gen, pri čemu mutirani spr gen kodira spr protein koji ima mutaciju u aminokiselini H145 prema aminokiselinskoj sekvenci SEK ID NO: 21, i(b) nerekombinantni hromozomski Tsp gen divljeg tipa. 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1000590.8A GB201000590D0 (en) | 2010-01-14 | 2010-01-14 | Bacterial host strain |
| EP11700144.6A EP2523975B1 (en) | 2010-01-14 | 2011-01-13 | Bacterial host strain comprising a mutant spr gene and a wild-type tsp gene |
| PCT/EP2011/050415 WO2011086138A1 (en) | 2010-01-14 | 2011-01-13 | Bacterial host strain comprising a mutant spr gene and a wild-type tsp gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03561B true ME03561B (me) | 2020-07-20 |
Family
ID=42028360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-281A ME03561B (me) | 2010-01-14 | 2011-01-13 | SOJ BAKTERIJA DOMAĆINA KOJI SADRŽI MUTIRANI SPR GEN I DIVLJI TIP Tsp GENA |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8969037B2 (me) |
| EP (1) | EP2523975B1 (me) |
| JP (1) | JP5960607B2 (me) |
| KR (1) | KR101741865B1 (me) |
| CN (1) | CN102712694B (me) |
| AU (2) | AU2011206586B2 (me) |
| BR (1) | BR112012016807B1 (me) |
| CA (1) | CA2785931C (me) |
| CY (1) | CY1122174T1 (me) |
| DK (1) | DK2523975T3 (me) |
| ES (1) | ES2747981T3 (me) |
| GB (1) | GB201000590D0 (me) |
| HR (1) | HRP20191815T1 (me) |
| HU (1) | HUE046420T2 (me) |
| LT (1) | LT2523975T (me) |
| ME (1) | ME03561B (me) |
| PL (1) | PL2523975T3 (me) |
| PT (1) | PT2523975T (me) |
| RS (1) | RS59417B1 (me) |
| SG (1) | SG182279A1 (me) |
| SI (1) | SI2523975T1 (me) |
| SM (1) | SMT201900550T1 (me) |
| WO (1) | WO2011086138A1 (me) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2480661A1 (en) | 2009-09-24 | 2012-08-01 | UCB Pharma, S.A. | Bacterial host strain |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) * | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| GB201012599D0 (en) * | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| MX348738B (es) * | 2011-07-13 | 2017-06-27 | Ucb Pharma Sa | Cepa huesped bacteriana que expresa dsbc recombinante. |
| EP2737050A4 (en) * | 2011-07-25 | 2015-01-21 | Pfizer | RECOMBINANT APOA-1M FROM MANIPULATED BACTERIA |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| US10358460B2 (en) | 2014-12-22 | 2019-07-23 | Ucb Biopharma Sprl | Protein manufacture |
| JP6991978B2 (ja) | 2016-01-27 | 2022-02-03 | メディミューン，エルエルシー | 定められるグリコシル化パターンを有する抗体を調製するための方法 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110055202B (zh) * | 2019-03-15 | 2023-08-22 | 百奥泰生物制药股份有限公司 | 用于高表达外源蛋白的大肠杆菌及其构建方法与应用 |
| US20240327849A1 (en) * | 2019-08-05 | 2024-10-03 | Wacker Chemie Ag | Bacterial strain for releasing a recombinant protein in a fermentation method |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| GB9215540D0 (en) | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| US5304472A (en) | 1992-11-20 | 1994-04-19 | Genentech, Inc. | Method of controlling polypeptide production in bacterial cells |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| JP2000083670A (ja) | 1998-09-09 | 2000-03-28 | Hsp Kenkyusho:Kk | ＤｓｂＡ／ＤｓｂＢ／ＤｓｂＣ／ＤｓｂＤ発現プラスミド |
| CA2377491C (en) | 1999-06-29 | 2008-01-29 | Siga Technologies, Inc. | Assay for degp protease inhibitors |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| AU2001287040A1 (en) | 2000-09-01 | 2002-03-13 | Biogen, Inc. | Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins |
| AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| US7041479B2 (en) | 2000-09-06 | 2006-05-09 | The Board Of Trustess Of The Leland Stanford Junior University | Enhanced in vitro synthesis of active proteins containing disulfide bonds |
| DE60135498D1 (de) | 2000-12-14 | 2008-10-02 | Genentech Inc | Produktion von ganzen Antikörpern in prokaryontischen Zellen |
| RU2287574C2 (ru) * | 2000-12-14 | 2006-11-20 | Дженентек, Инк. | БАКТЕРИЯ Е.coli, ПРОДУЦИРУЮЩАЯ ГЕТЕРОЛОГИЧНЫЙ ПОЛИПЕПТИД, И СПОСОБ ПРОДУЦИРОВАНИЯ ПОЛИПЕПТИДА |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| JP4461210B2 (ja) | 2001-08-27 | 2010-05-12 | ジェネンテック， インコーポレイテッド | 抗体発現系とその構築法 |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| EP2022799A2 (en) | 2001-11-16 | 2009-02-11 | Biogen Idec Inc. | Polycistronic expression of antibodies |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| GB0224082D0 (en) | 2002-10-16 | 2002-11-27 | Celltech R&D Ltd | Biological products |
| NZ538996A (en) | 2002-10-31 | 2008-04-30 | Genentech Inc | Methods and compositions for increasing antibody production |
| EP1570267B1 (en) | 2002-12-03 | 2011-10-12 | UCB Pharma, S.A. | Assay for identifying antibody producing cells |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| JP4667383B2 (ja) | 2003-06-13 | 2011-04-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用 |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| CN1894695A (zh) | 2003-07-26 | 2007-01-10 | 比奥根艾迪克Ma公司 | 具有改良的抗原结合亲和力的改变的抗体 |
| EA014226B1 (ru) | 2004-07-26 | 2010-10-29 | Байоджен Айдек Ма Инк. | Антитела к cd154, их фрагменты и способы применения антител и фрагментов |
| CA2577082A1 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| GB0425534D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
| GB0520169D0 (en) | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| PL2125894T3 (pl) | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
| US7662587B1 (en) | 2009-03-05 | 2010-02-16 | E. I. Du Pont De Nemours And Company | Gene knockout mutations that increase peptide production |
| EP2480661A1 (en) | 2009-09-24 | 2012-08-01 | UCB Pharma, S.A. | Bacterial host strain |
| US8470552B2 (en) | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| TWI600760B (zh) | 2009-11-05 | 2017-10-01 | 建南德克公司 | 分泌異源多肽之方法及組合物 |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000588D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| MX348738B (es) | 2011-07-13 | 2017-06-27 | Ucb Pharma Sa | Cepa huesped bacteriana que expresa dsbc recombinante. |
| EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
-
2010
- 2010-01-14 GB GBGB1000590.8A patent/GB201000590D0/en not_active Ceased
-
2011
- 2011-01-13 SI SI201131782T patent/SI2523975T1/sl unknown
- 2011-01-13 PL PL11700144T patent/PL2523975T3/pl unknown
- 2011-01-13 JP JP2012548440A patent/JP5960607B2/ja active Active
- 2011-01-13 EP EP11700144.6A patent/EP2523975B1/en active Active
- 2011-01-13 ES ES11700144T patent/ES2747981T3/es active Active
- 2011-01-13 CA CA2785931A patent/CA2785931C/en active Active
- 2011-01-13 CN CN201180005972.4A patent/CN102712694B/zh active Active
- 2011-01-13 BR BR112012016807A patent/BR112012016807B1/pt not_active IP Right Cessation
- 2011-01-13 US US13/522,080 patent/US8969037B2/en active Active
- 2011-01-13 AU AU2011206586A patent/AU2011206586B2/en not_active Ceased
- 2011-01-13 PT PT117001446T patent/PT2523975T/pt unknown
- 2011-01-13 HU HUE11700144A patent/HUE046420T2/hu unknown
- 2011-01-13 LT LTEP11700144.6T patent/LT2523975T/lt unknown
- 2011-01-13 KR KR1020127021019A patent/KR101741865B1/ko active Active
- 2011-01-13 WO PCT/EP2011/050415 patent/WO2011086138A1/en not_active Ceased
- 2011-01-13 ME MEP-2019-281A patent/ME03561B/me unknown
- 2011-01-13 HR HRP20191815TT patent/HRP20191815T1/hr unknown
- 2011-01-13 SM SM20190550T patent/SMT201900550T1/it unknown
- 2011-01-13 DK DK11700144.6T patent/DK2523975T3/da active
- 2011-01-13 SG SG2012047668A patent/SG182279A1/en unknown
- 2011-01-13 RS RSP20191294 patent/RS59417B1/sr unknown
-
2015
- 2015-02-27 US US14/633,257 patent/US9493558B2/en active Active
-
2017
- 2017-01-27 AU AU2017200545A patent/AU2017200545B2/en not_active Ceased
-
2019
- 2019-10-11 CY CY20191101071T patent/CY1122174T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03561B (me) | SOJ BAKTERIJA DOMAĆINA KOJI SADRŽI MUTIRANI SPR GEN I DIVLJI TIP Tsp GENA | |
| Yang et al. | Generation of an artificial double promoter for protein expression in Bacillus subtilis through a promoter trap system | |
| Chou | Engineering cell physiology to enhance recombinant protein production in Escherichia coli | |
| HRP20150659T1 (hr) | Domaä†inski soj bakterija koji sadrži mutirani spr gen te ima smanjenu tsp aktivnost | |
| CN103298828A (zh) | 犹他游动放线菌的基因组学 | |
| IN2012DN02401A (me) | ||
| JP2015516166A5 (me) | ||
| TWI654304B (zh) | 具提升酶活性的溶菌酶 | |
| CN108779154B (zh) | 增强的蛋白质产生及其方法 | |
| JP2020509763A5 (me) | ||
| CN115960802B (zh) | 高产重组蛋白的需钠弧菌工程菌及其应用 | |
| US10030257B2 (en) | Separatome-based protein expression and purification platform | |
| CN108570477B (zh) | 一种碱性蛋白酶基因及其重组枯草芽孢杆菌菌株的构建方法 | |
| CN107759675A (zh) | 一种来源于枯草芽孢杆菌可提高分泌效率的信号肽及其应用 | |
| JP5294666B2 (ja) | 組換え微生物 | |
| CN107936096A (zh) | 一种能有效提高蛋白分泌效率的信号肽及其应用 | |
| CN107868781A (zh) | 人工合成mar片段、表达载体、表达系统及其应用 | |
| DK1905839T4 (da) | Fremgangsmåde til fermentativ fremstilling af proteiner | |
| JP5044085B2 (ja) | 原核宿主細胞における組換えタンパク質の生産 | |
| Han et al. | Fabrication and characterization of a robust and strong bacterial promoter from a semi-rationally engineered promoter library in Bacillus subtilis | |
| CN107541482B (zh) | 一种构建大肠杆菌高效分泌表达转肽酶Sortase A的方法 | |
| JP2013066446A (ja) | σＤ因子抑制解除株及びそれを用いたタンパク質の製造方法 | |
| Sulthana et al. | Whole-genome shotgun sequencing and characterization of probiotic strain Clostridium butyricum UBCB 70 to assess its safety | |
| CN116640713A (zh) | 基于fimC基因敲除的哈维弧菌高接合转移效率菌株及其构建方法和应用 | |
| CN103194462A (zh) | 枯草芽孢杆菌谷氨酰胺合成酶基因、其编码蛋白及其克隆方法 |